Grants and Philanthropy
Dr. Daniel Malamud and UMDNJ Share $3.2 Million NIH Grant for HIV Prevention Research

Seated, from left: Dr. Neville Kallenbach, NYU School of Medicine; Dr. Daniel Malamud, NYUCD; Dr. Drew Weissman, University of Pennsylvania School of Medicine
Standing, from left: Dr. William Abrams, NYUCD; Dr. Min Lu, UMDNJ-New Jersey Medical School; Ms. Cheryl Barber, NYUCD; Dr. Zoya Kurago, NYUCD; Ms. Veronica Holmes, University of Pennsylvania School of Medicine; Dr. Ramiro Murata, NYUCD

The National Institute of Allergy & Infectious Diseases, part of the National Institutes of Health, has awarded a joint, five-year, $3.2 million grant to the NYU College of Dentistry and the University of Medicine and Dentistry of New Jersey (UMDNJ) to conduct the first study to evaluate whether gp340, a protein found in saliva and other mucosal secretions, can prevent HIV transmission in vivo. The study is being led by Dr. Daniel Malamud, professor of basic science and craniofacial biology and director of the HIV/AIDS Research Program at the NYU College of Dentistry, and Dr. Min Lu, professor of microbiology and molecular genetics at the Public Health Research Institute Center of the UMDNJ-New Jersey Medical School. Dr. Malamud will generate the gp340 molecules and smaller fragments of the molecule for laboratory analysis, and Dr. Lu will analyze the biophysical interactions of these proteins with HIV.

Dr. Malamud's research on the antiviral activity of gp340 and other human salivary proteins has been funded by the NIH for over 25 years. Although it has been established that salivary proteins can protect against the HIV virus, the mechanisms by which the proteins offer protection are not fully understood.

Gp340 was shown to inhibit HIV transmission in earlier in vitro research. Dr. Malamud and Dr. Lu will evaluate gp340 antiviral activity in mice that have had their immune systems replaced with an implanted human immune system—an experimental model developed by Dr. Victor Garcia-Martinez, professor of medicine at the University of North Carolina School of Medicine and a co-investigator on the study.

The researchers will inject the mice's salivary glands with a vector carrying a gene that produces the portion of gp340 that has been identified as inhibiting HIV infection. Once the mice have secreted the gp340 fragments in their saliva, the investigators will inject HIV into the oral cavity. They will also inject a second group of mice that has not been injected with the gp340 gene with HIV and will compare the two groups to determine whether gp340 protected the first group from infection.

The study will also analyze the impact of gp340 on HIV transmission in the mouse female reproductive tract. Previous in vitro research has suggested that gp340 on the surface of cells in the reproductive tract may enhance HIV infection by binding HIV to vaginal cells. The researchers plan to assess whether introducing soluble gp340 into the female reproductive tract would override the binding of surface cells to HIV and reduce HIV infection.

Findings from the study could help in the development of new antiviral drugs to protect against HIV.

In addition to Dr. Garcia-Martinez, co-investigators on the study include Dr. William Abrams, research professor in the department of basic science and craniofacial biology, and Ms. Cheryl Barber, a research scientist in the department of basic science and craniofacial biology, both at the NYU College of Dentistry.